Background: Prolonged-release fampridine (PR-fampridine, 4-aminopyridine) increases walking speed in the timed 25-foot walk test (T25FW) in some patients (timed-walk responders) with multiple sclerosis (MS). Objective: To explore the effects of PR-fampridine on different aspects of walking function and to identify associated gait modifications in subjects with MS. Methods: In this prospective, randomized, placebo-controlled, double-blind, phase II study (FAMPKIN; clinicaltrials.gov, NCT01576354), subjects received a 6-week course of oral placebo or PR-fampridine treatment (10 mg, twice daily) before crossing over. Using 3D-motion-analysis, kinematic and kinetic parameters were assessed during treadmill walking (primary endpoint). Clinical outcome measures included T25FW, 6-minute walk test (6MWT), and balance scales. Physical activity in everyday life was measured with an accelerometer device. Results: Data from 55 patients were suitable for analysis. Seventeen subjects were timed-walk responders under PR-fampridine. For the total study population and for responders, a significant increase in walking speed (T25FW) and distance (6MWT) was observed. Gait pattern changes were found at the single-subject level and correlated with improvements in the T25FW and 6MWT. Physical activity was increased in responders. Conclusion: PR-fampridine improves walking speed, endurance, and everyday physical activity in a subset of subjects with MS and leads to individual modifications of the gait pattern.
Introduction
In multiple sclerosis (MS), walking impairment is a common consequence of the immune-mediated inflammatory destruction of myelin sheaths, axons, and neurons in the human central nervous system (CNS). Ambulatory function is rated as most valuable by patients with early and advanced MS, while subclinical gait abnormalities can be found even in the early stages of the disease. 1, 2 MS lesions can occur at different locations within the CNS and may affect the anatomical systems important for walking and motor control to varying degrees. 3 Resultant symptoms, including paresis, sensory deficits, spasticity, and fatigue, interfere with different aspects of walking function such as gait velocity, endurance, and balance. Consequently, MS represents a particularly heterogeneous disease even at the level of a single, albeit multi-factorial, symptom such as walking dysfunction.
At present, various disease-modifying immunotherapies for MS are available, but treatment options to specifically improve MS-related walking disturbances remain limited. 4, 5 Two phase III trials showed that oral administration of prolonged-release fampridine (PR-fampridine; dalfampridine) increases walking speed in the timed 25-foot walk test (T25FW) in a subset of patients with MS (timed-walk responders). [6] [7] [8] The active substance 4-aminopyridine (4-AP) leads to improved signal conduction in demyelinated axons via the blockade of voltage-gated potassium channels. 9 This increase in walking speed was first observed 2 weeks after the initiation of treatment, was clinically relevant as indicated by a patient-based walking scale (12-item MS Walking Scale (WS), 12-item WS), and was independent of demographic factors or the type of MS. 8, 10, 11 However, it remains unclear how this increased walking speed was achieved, for example, through improved strength or balance, or reduced motor fatigue.
The objective of the present investigator-initiated phase II trial ("FAMPKIN") was (1) to further characterize the effects of PR-fampridine on different aspects of walking function in subjects with MS, (2) to analyze the relevance of PR-fampridine-induced improvements in the patients' daily life, and (3) to identify the modification of gait patterns underlying the beneficial effects of PR-fampridine.
Patients and methods

Study participants
Sixty-one outpatients (Figure 1(a) ) aged 18-65 years with a diagnosis of relapsing-remitting (RRMS), primary (PPMS), or secondary progressive (SPMS) MS 12 were included (Table 1 ). Patients were recruited at the University Hospital Zurich, Switzerland, in 2012 and 2013. Participants had a clinically apparent walking impairment (e.g. ataxia, paresis of leg muscles, or restricted walking duration) but were able to cover a distance of at least 50 m within 6 minutes with or without walking aids. Patients with a history of seizure, prior exposure to 4-AP, or other conditions impeding gait, such as cardiac, pulmonary, or orthopedic diseases, were excluded. Subjects who experienced MS relapses or whose MS therapy changed during the study were excluded from final analyses. Changes in concomitant medication and adverse events (AEs) were recorded at each visit. The study was conducted in accordance with the guidelines of the Declaration of Helsinki and the Good Clinical Practice guidelines and approved by the Zurich cantonal ethics committee and Swissmedic. All participants gave written informed consent. Subjects did not receive payment for participation in the trial. The trial, named FAMPKIN, was registered at clinicaltrials.gov (NCT01576354). Monitoring was conducted by the Clinical Trials Center of the University Hospital Zurich, Switzerland.
Study design
This explorative study was a prospective, singlecenter, randomized, placebo-controlled, doubleblind, phase II trial with a crossover design ( Figure  1(b) ). After screening, 13 study visits took place including five baseline visits (visits 0, 1, 2, 7, and 12). After a single-blind, placebo run-in period of 2 weeks, subjects were randomized at a 1:1 ratio to receive double-blind treatment with either placebo or 10 mg PR-fampridine every 12 hours for 6 weeks. Patients then all received single-blind placebo treatment for 2 weeks (washout period), followed by another 6 weeks of double-blinded treatment. Subjects who received PR-fampridine during the first double-blind treatment period received placebo in the second period and vice versa (crossover). A 2-week observation period was maintained after the second treatment period. Blinding and randomization were performed by the Zurich cantonal pharmacy. All subjects and staff were blinded to treatment assignments. PR-fampridine matrix tablets and matching placebo tablets were provided by Biogen. Subject treatment compliance was confirmed by counting the tablets remaining in the returned boxes.
Outcome measures
Clinical assessments, questionnaires, activity monitoring, and gait analyses were performed at different time points as illustrated in Supplementary Table 1 . Clinical walking and balance tests including the T25FW, 6-minute walk test (6MWT), the timed upand-go test (TUG), Berg balance scale (BBS), dynamic gait index (DGI), and the lower extremity manual muscle test (LEMMT) were conducted as reported previously. 6, 7, [13] [14] [15] [16] [17] Subjects who used walking aids in the clinical tests at screening continued to use the same devices for all subsequent tests. Timedwalk responders were subjects with a faster walking speed in the T25FW for at least three of the four visits during the double-blind treatment periods as compared with the maximum speed achieved in the five baseline visits. 6, 7 Patients' perception of their treatment's effects was evaluated using the 12-item WS for walking function (maximal score of 60 points) 18 and the Wurzburg Fatigue Inventory for Multiple Sclerosis for motor and cognitive fatigue (WEIMuS; maximal score for cognitive fatigue 36 points, motor fatigue 32 points). 19 Subjects were asked to wear an accelerometer device (Actiwatch 2, Philips Respironics, USA) attached to the ankle of the more impaired leg (MIL) (based on the neurological examination) for 14 consecutive days during each of the two double-blind treatment phases and to keep a sleep diary over this period. The device was a small piezo-electric acceleration sensor with a sensitivity of 0.025 G and a sampling rate of 32 Hz. Using the Actiware software (V6.0.1), motion was measured in activity counts averaged over 15-second intervals. 20 Three-dimensional gait analysis was conducted while walking on an instrumented treadmill (120 Hz, FDM-THM-M System, zebris Medical GmbH, Germany) using 14 infrared cameras (Vicon, UK) with a sampling rate of 200 Hz. Small reflective markers attached to the subjects' skin overlying anatomical landmarks at the trunk, and the upper and lower extremities allowed for three-dimensional reconstruction of movements using a full-body gait model (Plug-in-Gait, Vicon, UK). Vertical ground reaction force data were exported from the treadmill's integrated capacitive pressure platform 21 normalized to body weight and the area under the force curve determined using a custom-made Matlab script (Mathworks, Inc., USA). Gait analysis was performed twice during each double-blind treatment period ( Supplementary Table 1 ). Subjects walked barefoot on the horizontal treadmill and were continuously secured by a fall-stop system. Treadmill speed was set to 80% of the mean maximal overground walking speed as assessed in the T25FW at Visit 0 and 1. Treadmill speed and other conditions (e.g. use of handrails) were kept constant for all sessions for each subject. Gait was assessed over a period of 30 seconds per visit (10-20 step cycles). Analysis comprised 15 of the most relevant kinematic and kinetic gait parameters and was conducted in Vicon Nexus (V1.8.5) and ProCalc (Vicon, UK). 2,22-24 A significant change in kinematic parameters under treatment with PR-fampridine was defined as the study's primary endpoint. T25FW (including responder status), 6MWT, TUG, BBS, DGI, LEMMT, 12-item WS, WEIMuS, accelerometer data, and sleep duration were defined as secondary outcomes.
Safety assessments included a physical examination, resting electrocardiogram, vital signs, and laboratory tests comprising hematology, blood chemistry, and urine analysis ( Supplementary Table 1 ).
Statistics
Statistical analysis was performed with SPSS (V21, IBM Corp., USA), GraphPad Prism 5 (V5.01, GraphPad Software, Inc., USA), and Matlab (Mathworks, Inc., USA). For data presentation, groups of all subjects, fampridine-responders, and fampridine-and placebo-non-responders were designated. Fisher's exact test was applied to determine significant differences in the incidence of AEs under treatment with placebo and PR-fampridine. For clinical gait measures, activity parameters, fatigue, sleep duration, kinematic and kinetic parameters, twotailed, paired t-tests were performed to detect differences between placebo and PR-fampridine treatment.
Holm's sequential Bonferroni procedure was applied to adjust for multiple comparisons. Repeated measures one-way analysis of variance (ANOVA) was used to analyze changes of walking speed (T25FW) over time in the responder subgroup. To reduce dimensionality of the dataset, linearly uncorrelated components (principal components, PCs) were identified using an alternating least-squares algorithm on the centered and standardized dataset with Kaiser-Guttman stopping criteria. 25 Each data-point subsequently underwent orthogonal linear transformation to determine its loading in PC-space. Translation between treatment conditions in the PC-space was quantified for each data pair (patient treated with placebo or PR-fampridine) in each dimension and group clustering was characterized through volume shifts in a fitted convex hull. To test for differences of translations between treatments, a two-tailed paired t-test was applied. Changes of kinematic parameters at the single-subject level were evaluated by calculating the between-measurement variability (measurement error) within each double-blind treatment period for each parameter. Between-measurement variability under treatment with PR-fampridine and placebo was similar ( Supplementary Table 2 ); therefore, an overall mean between-measurement variability was determined for each parameter. Changes of kinematic parameters under treatment with PR-fampridine compared to placebo exceeding the threshold of the between-measurement variability ±2 standard deviations were defined as relevant.
Results
We assessed 131 subjects with MS for eligibility, of whom 64 subjects were screened and 61 randomly assigned to treatment (Figure 1(a) ). One subject withdrew before completing the second double-blind treatment period. Sixty patients completed the trial. Five subjects were excluded from final analysis (one MS relapse, one subject broke his leg and, three noncompliance with the study drug). Data from 55 patients were thus available for analysis. Oral administration of PR-fampridine for 6 weeks was well tolerated and showed no significant side effects compared to placebo treatment ( Table 2 ). In the T25FW, 17 of 55 subjects (31%) met the timed-walk responder criterion 6, 7 under treatment with PR-fampridine (fampridine-responders; Figure 2 ). The number of responders was similar in both study arms (8 vs 9 subjects). Three subjects met the responder criterion only under placebo (placebo-responders), while five did so during both treatment periods (double-responders); these groups were not classified as responders. Thirty subjects were classified as non-responders (55%). Compared to baseline performance, responders showed a mean increase of walking speed of 14% in the T25FW under PR-fampridine. This gain was significantly higher than the 2% increase in walking speed observed under placebo (p < 0.0001) and was already present 1 week after the initiation of treatment (Figure 2 (b) and (c)). Significantly increased walking speed under PR-fampridine persisted as an effect when determined for the entire study population (p < 0.0001; 9% change from baseline), but was not evident in the non-responder group when analyzed alone. Walking distance in the 6MWT increased significantly for all patients under treatment with PR-fampridine (p < 0.0001 compared to placebo; 4% change from baseline; Figure 2(d) ). This effect was more pronounced in the responders (p = 0.0004 compared to placebo; 8% change from baseline). Treatment with PR-fampridine did not induce significant changes in the other clinical tests comprising the TUG (Figure 2(e) ), LEMMT, BBS, and DGI or in the 12-item WS ( Supplementary Figure 1 ). For the total study population, no significant changes in cognitive or motor fatigue were detected during treatment with PR-fampridine ( Supplementary Figure 2(A) and (B) ).
There was a trend toward a reduction in cognitive (p = 0.253) and, especially, motor (p = 0.0534) fatigue in the responders under treatment with PR-fampridine.
Sleep duration tended to be slightly shorter (about 12 minutes per day in the total study population; p = 0.0294) under PR-fampridine ( Supplementary  Figure 2 (C)).
One subject declined to wear the accelerometer, leaving 54 datasets for analysis. Physical activity assessed with this device was not significantly altered by PR-fampridine in the total study population, but showed a significant increase in activity counts per day during the waking phase in responders (p = 0.0045; Figure 3 (a) and (b)). The cumulative time spent active per day did not differ in subjects between PR-fampridine and placebo treatment in any group, indicating that the increase in activity counts is driven by intensity rather than duration of physical activity in responders (Figure 3(c) ).
One subject was unable to walk on the treadmill at 80% of his overground T25FWT speed and was excluded from the kinematic and kinetic analysis (n = 54). Compared to placebo, averaged group values of most of the kinematic and kinetic measures assessed during treadmill walking were not altered by PR-fampridine (Table 3 ). In the total study population, there was a statistically significant increase of knee range of motion (ROM) in the more (MIL; p < 0.0001) and the less impaired leg (LIL; p = 0.0006) during treatment with PR-fampridine. However, these changes were small, with a difference in ROM of only 2°. Alternating least-squares identification of PC revealed three components with eigenvalues greater than 1 which together accounted for about 90% of the total variance ( Supplementary Figure 3) . Translation between treatments was not significantly different between groups on any component. Point dispersion and centroid location were similar for placebo and PR-fampridine treatment. Thus, PC analysis showed no significant changes under treatment with PR-fampridine in comparison to placebo at the group level.
At the single-subject level, we observed heterogeneous fampridine-induced modifications of the gait pattern in a subset of patients. Some individuals showed a strongly increased ROM in the knee under PR-fampridine (Figure 4 (a)-(c); subject 31 in Figure  5 (a) and (b)), while other subjects, for instance, demonstrated a greater ROM in the hip joint (subject 9 in Figure 5 (a) and (b)). Using the between-measurement variability ±2 standard deviations as a threshold, single-subject analysis showed that 25 of the 54 subjects (46%) demonstrated relevant changes in at least one gait parameter ( Figure 5(b) ). Type and magnitude of modifications differed considerably across subjects and were not restricted to the MIL or the LIL. Proportionally, more subjects with at least one altered parameter under PR-fampridine were in the responder than the non-responder subgroup ( Figure  5 (c)). Subjects with at least one changed kinematic parameter under treatment with PR-fampridine demonstrated significantly larger increases of walking speed in the T25FW (two-tailed unpaired t-test: p = 0.0066, Figure 5(d) ) and walking distance in the 6MWT (two-tailed unpaired t-test: p = 0.0114, Figure  5 (e)) than subjects without such gait pattern changes, indicating that walking improvements under PR-fampridine are based on individual modifications of the gait pattern.
Discussion
The objective of this explorative, investigator-initiated phase II trial was to characterize the effects of PR-fampridine on different aspects of walking impairment in subjects with MS, using a comprehensive gait analysis protocol including clinical tests, questionnaires, and biomechanical parameters. Since MS is a chronic condition and PR-fampridine has a half-life in the range of a few hours, 26 we chose a crossover study design to compensate for the limited number of eligible subjects in this single-center trial. A washout period of 2 weeks appeared to be sufficient to avoid carryover effects (see Figure 2 (b)).
We found that roughly one-third of the patients met the timed-walk responder criterion defined by Goodman et al. under treatment with PR-fampridine, in line with the results from the previous pivotal trials. 6, 7 Walking speed increased in responders by an average of 14% in the T25FW under treatment with PR-fampridine, a somewhat smaller effect than the 20%-25% increase reported for responders in the larger pivotal trials. 8 This difference in effect sizes may explain the absence of a significant change in the related patient-based outcome measure of walking function. In the previous trials, the 12-item WS was used to show that the effects of PR-fampridine were clinically meaningful. 6, 7, 10, 11 In the present study, clinical relevance of the observed improvements was demonstrated by the accelerometer data, showing for the first time that treatment with PR-fampridine enhances physical activity in everyday life in responders. However, the type of physical activity (e.g. walking, running, climbing stairs) that increased with PR-fampridine could not be determined with our device. We also demonstrated that PR-fampridine not only increased maximal walking speed but also the walking distance achieved in the 6MWT, indicating improved walking endurance. 27 There was no effect of the study drug on static and dynamic balance, which is in contrast to findings from the recent MOBILE trial. 28 Factors limiting the use of the BBS and the DGI scores as outcome measures in the present study may include its small sample size (n = 55) and the low sensitivity and inherent ceiling effects of such scales.
The main objective of the present study was to uncover the functional mechanisms that drive improvements in the T25FW and 6MWT. We used gold standard 3D-gait analysis to identify mechanisms underlying gait disturbances. 29 There was only a single common effect of PR-fampridine treatment-a significant increase of the ROM in the knee joint. However, this ROM change was minor, casting doubt on its clinical relevance and contribution to the observed improvements. Using a descriptive statistical approach based on the between-measurement variability to evaluate treatment effects at the single-subject level, we observed extensive but heterogeneous alterations of the biomechanical parameters in about half of subjects. The incidence of gait parameter changes significantly correlated with improvements in the T25FW and 6MWT under treatment with PR-fampridine. Subjects with MS can experience a variety of neurological impairments, and this heterogeneity may also be reflected in MS-related gait disturbances where different aspects of ambulatory function can be affected to varying degrees. In our cohort, subjects were affected with a wide range of gait disturbances characterized by, for example, spasticity, sensory and cerebellar ataxia, or weakness of the leg muscles. Therefore, the individual kinematic adaptations observed in our data during treatment with PR-fampridine may be anchored in both deficit-specific improvements and individual compensatory strategies.
Finally, the safety data of our trial confirmed good tolerability of PR-fampridine. 6, 7 In the earlier trials, urinary tract infections (UTIs) occurred more frequently in patients treated with PR-fampridine in comparison to placebo. 6, 7 We did not observe a higher incidence of UTIs, in line with the findings of a recently published post hoc analysis. 30 To conclude, our findings indicate that treatment with PR-fampridine is well tolerated and improves walking speed, endurance, and physical activity in a subset of subjects with MS. Improvements of ambulatory function are achieved through individual modification of the gait pattern. and M.F. collected, analyzed and interpreted the data. B.Z. and C.S.E. analyzed the data and performed statistics. A.C. participated in the enrollment and assessment of study participants. M.W. and M.L. conceived and supervised the study and critically revised the manuscript.
